ClinicalTrials.gg
CompletedNCT03488563Updated Oct 4, 2022Results posted

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

A Phase 2 interventional study of B244 and Vehicle in Migraine, sponsored by AOBiome LLC. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by AOBiome LLC · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
155th of 609
313 · median 78
Started
2018
with 26 others
Phase 2
90 of 696
7 open now
Registered
378th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 155th largest by enrollment of the 609 interventional ones that give a count, is one of 27 that started in 2018, is one of 90 in phase 2, and was the 378th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.

Read the detailed description

This is a Prospective, Randomized, Vehicle-controlled, Double-blind, Multi-center, 3-arm study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.

At Screening and Baseline, all subjects must experiences 4-14 migraine days per month and 3-14 migraine attacks per month and no more than 14 headache days per month in the 3 months prior to screening.

The total duration of the study will be approximately 16 weeks. Participants will report for a Screening visit and if all inclusion criteria are met, subjects will go through a one month baseline period prior to randomization. Subjects will come in for visits at Day 28 (Week 4), Day 56 (Week8), Day 84 (Week12), and Day 112 (Week 16).

Efficacy will be assessed by change in migraine attacks, days, and hours. Blood and urine samples will be collected for standard safety laboratory testing and the effect of the drug on inflammatory biomarkers. Safety will be monitored throughout the study.

Investigators plan to enroll 303 total subjects. Subjects will be randomized 1:1:1 so that an equal number of subjects will be treated in each arm of the study.

03

Conditions studied

  • Migraine

Keywords

  • Headache
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females, 18 to 65 years of age.
  • In good general health as determined by a thorough medical history and physical examination, and vital signs.
  • At least a 1-year history of migraine with or without aura that began before the age of 50 years old and consistent with a diagnosis of migraine with or without aura according to the International Classification of Headache Disorders, 3rd edition, beta version.
  • Experiences 4-14 migraine days per month and 3-14 migraine attacks per month and no more than 14 headache days per month (including migraine and non-migraine headache days) in the 3 months prior to screening.
  • Experiences 4-14 migraine headache days per month during the baseline period.
  • Ability and willingness to abstain from taking medications not allowed by the protocol or administering any foreign substance intranasally.
  • Ability and willingness to complete a migraine-history diary from screening to treatment with study drug and a migraine-treatment diary from prevention treatment through the remainder of the follow-up period.

Exclusion criteria

Exclusion Criteria:

  • Headache on greater than 14 days/month in any of the three months (90 days) preceding entry into the study.
  • Use of acute migraine-specific medications (e.g., ergotamine, triptan) on more than 10 days per month in the previous 3 months and during study.
  • Use of intranasal migraine medications during study.
  • Use of any intranasally administered over-the-counter product or nasal irrigation (e.g., neti pot) during study.
  • Opioids/barbiturates used on more than 4 days per month in the previous 3 months and throughout the duration of the study.
  • Use of analgesics (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], acetylsalicylic acid, or combination analgesics) for migraine and non-migraine headaches on more than 14 days per month in the - Use of migraine prevention medication within two months prior to study and throughout the duration of the study.
  • Botulinum toxin injection within 3 months prior to screening or during study.
  • Anti-CGRP monoclonal antibody (e.g., erenumab, fremanezumab, galcanezumab, and eptinezumab) injection or infusion within 4 months prior to screening or during study.
  • Small molecule anti-CGRP medications in the 30 days prior to the screening visit.
  • Use of systemic antibiotics during study.
  • Pregnancy or breast-feeding.
  • Female of not using adequate measures.
  • Inability to give .
  • History of neurological, psychiatric, or any other medical condition that in the opinion of the investigator may compromise the subject's ability to safely participate in the study.
  • Subjects with any significant clinical abnormalities which may interfere with study participation.
  • Prior use of AO+ Mist.
  • Subjects with immunodeficiencies, nasal lesions, nasal polyps, or sinus infections.
  • Subjects who have participated in an drug trial in the 30 days prior to the screening visit.
  • Inability to maintain at least 80% diary compliance during the study from baseline to follow-up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    B244 Dose 1

    B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day

    Biological: B244

  • Experimental
    B244 Dose 2

    B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day

    Biological: B244

  • Placebo comparator
    Vehicle

    Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day

    Biological: Vehicle

Interventions

  • BiologicalB244

    B244 Suspension

  • BiologicalVehicle

    Vehicle Suspension

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

    Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.

    Time frame: Baseline to Day 112

Secondary outcomes

  1. Mean Change in Monthly Migraine Days.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).

    Time frame: Baseline to Day 84

  2. Mean Change in Monthly Migraine Attacks.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine attacks (an episode of any qualified migraine headache. To distinguish an attack of long duration from two attacks or to distinguish between attacks and relapses: A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of the recurrence) will be considered as one attack and not two. -An attack treated successfully with medication but with relapse within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of recurrence) will be considered as one attack.)

    Time frame: Baseline to Day 84

  3. Proportion of Subjects Experiencing a 50%, 75%, and 100% Reduction in Monthly Migraine Days.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).

    Time frame: Baseline to Day 112

  4. Mean Change in Monthly Acute Migraine Specific Medication Days.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included use of rescue (acute migraine specific) medications and dosing administration.

    Time frame: Baseline to Day 84

  5. Mean Change in Monthly Headache Days.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on headache days (a non-migraine headache day)

    Time frame: Baseline to Day 84

  6. Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)

    The Migraine Disability Assessment (MIDAS) questionnaire was administered to study examine the relationship between the impact of migraine and quality of life where subjects scored 5 questions on a scale of 0 to 21+ (0-5=little or no disability, 6-10=mild disability, 11-20=moderate disability, 21+=severe disability). The total score ranges from 0 to 90.

    Time frame: Baseline to Day 84

  7. Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire

    The Headache Impact Test-6 (HIT-6) questionnaire was administered to examine the relationship between impact of migraine and quality of life. The total score ranges from 36 to 78 where a higher score indicates a greater impact on quality of life (Class I: 36-49, Class II: 50-55, Class III: 56-59, Class IV: 60+).

    Time frame: Baseline to Day 84

  8. Mean Change From Baseline to 12 Weeks of Treatment in Monthly Migraine Specific Quality of Life Questionnaire (MSQL)

    The Migraine Specific Quality of Life (MSQL) questionnaire was used to examine the impact of migraine on health-related quality of life across three domains: Role Function-Restrictive (7 questions) examines the degree to which performance of daily activities is limited by migraine; Role Function-Preventive (4 questions) examines the degree to which performance of daily activities is prevented by migraine; Emotional Function (3 questions) examines feelings of frustration and helplessness due to migraine. Total score for each domain ranges from 0 to 100, where a higher score indicates greater severity.

    Time frame: Baseline to Day 84

Other outcomes

  1. Mean Change in Days Where Subject Recorded Migraine Associated Symptoms: Nausea/Vomiting, Photophobia and Sonophobia.

    Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine associated symptoms: nausea/vomiting, photophobia and sonophobia.

    Time frame: Baseline to Day 112

07

Results

Posted Oct 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneB244 Dose 1B244 Dose 2Vehicle
Started105104104
Completed838881
Not completed221623
Withdrew: Lost to follow-up767
Withdrew: Withdrawal by subject877
Withdrew: Physician decision001
Withdrew: Protocol violation326
Withdrew: Subject did not meet minimum number of migraines per month100
Withdrew: Use of prohibited medication200
Withdrew: Adverse event101
Withdrew: Subject returned for et visit010
Withdrew: Sponsor's decision001

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.

Time frame:
Baseline to Day 112
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
ParticipantsB244 Dose 1B244 Dose 2Vehicle
At Least 1 Treatment-Related TEAE181317
At Least 1 Treatment-Related Grade 3 or 4 TEAE101
At Least 1 Treatment-Related Serious TEAE000
SecondaryMean Change in Monthly Migraine Days.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).

Time frame:
Baseline to Day 84
Reported as:
Mean · days per month
Mean Change in Monthly Migraine Days.
days per monthB244 Dose 1B244 Dose 2Vehicle
Mean Change in Monthly Migraine Days.-3.2 ± 4.53-3.0 ± 4.04-3.4 ± 3.77
SecondaryMean Change in Monthly Migraine Attacks.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine attacks (an episode of any qualified migraine headache. To distinguish an attack of long duration from two attacks or to distinguish between attacks and relapses: A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of the recurrence) will be considered as one attack and not two. -An attack treated successfully with medication but with relapse within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of recurrence) will be considered as one attack.)

Time frame:
Baseline to Day 84
Reported as:
Mean · attacks
Mean Change in Monthly Migraine Attacks.
attacksB244 Dose 1B244 Dose 2Vehicle
Mean Change in Monthly Migraine Attacks.-2.0 ± 2.83-2.1 ± 2.43-2.0 ± 2.69
SecondaryProportion of Subjects Experiencing a 50%, 75%, and 100% Reduction in Monthly Migraine Days.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).

Time frame:
Baseline to Day 112
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing a 50%, 75%, and 100% Reduction in Monthly Migraine Days.
ParticipantsB244 Dose 1B244 Dose 2Vehicle
Week 12 : ≥50% Reduction313632
Week 12 : ≥75% Reduction201717
Week 12 : 100% Reduction1087
Week 16 : ≥50% Reduction242020
Week 16 : ≥75% Reduction12712
Week 16 : 100% Reduction1033
SecondaryMean Change in Monthly Acute Migraine Specific Medication Days.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included use of rescue (acute migraine specific) medications and dosing administration.

Time frame:
Baseline to Day 84
Reported as:
Mean · days
Mean Change in Monthly Acute Migraine Specific Medication Days.
daysB244 Dose 1B244 Dose 2Vehicle
Mean Change in Monthly Acute Migraine Specific Medication Days.-2.0 ± 5.62-2.5 ± 3.70-2.9 ± 4.26
SecondaryMean Change in Monthly Headache Days.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on headache days (a non-migraine headache day)

Time frame:
Baseline to Day 84
Reported as:
Mean · days
Mean Change in Monthly Headache Days.
daysB244 Dose 1B244 Dose 2Vehicle
Mean Change in Monthly Headache Days.-3.5 ± 4.66-3.4 ± 3.96-4.2 ± 3.79
SecondaryMean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)

The Migraine Disability Assessment (MIDAS) questionnaire was administered to study examine the relationship between the impact of migraine and quality of life where subjects scored 5 questions on a scale of 0 to 21+ (0-5=little or no disability, 6-10=mild disability, 11-20=moderate disability, 21+=severe disability). The total score ranges from 0 to 90.

Time frame:
Baseline to Day 84
Reported as:
Mean · score on a scale
Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)
score on a scaleB244 Dose 1B244 Dose 2Vehicle
Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)-10.0 ± 24.83-18.0 ± 39.43-13.8 ± 23.82
SecondaryMean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire

The Headache Impact Test-6 (HIT-6) questionnaire was administered to examine the relationship between impact of migraine and quality of life. The total score ranges from 36 to 78 where a higher score indicates a greater impact on quality of life (Class I: 36-49, Class II: 50-55, Class III: 56-59, Class IV: 60+).

Time frame:
Baseline to Day 84
Reported as:
Mean · score on a scale
Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire
score on a scaleB244 Dose 1B244 Dose 2Vehicle
Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire-4.3 ± 6.72-6.2 ± 7.68-5.7 ± 7.54
SecondaryMean Change From Baseline to 12 Weeks of Treatment in Monthly Migraine Specific Quality of Life Questionnaire (MSQL)

The Migraine Specific Quality of Life (MSQL) questionnaire was used to examine the impact of migraine on health-related quality of life across three domains: Role Function-Restrictive (7 questions) examines the degree to which performance of daily activities is limited by migraine; Role Function-Preventive (4 questions) examines the degree to which performance of daily activities is prevented by migraine; Emotional Function (3 questions) examines feelings of frustration and helplessness due to migraine. Total score for each domain ranges from 0 to 100, where a higher score indicates greater severity.

Time frame:
Baseline to Day 84
Reported as:
Mean · score on a scale
Mean Change From Baseline to 12 Weeks of Treatment in Monthly Migraine Specific Quality of Life Questionnaire (MSQL)
score on a scaleB244 Dose 1B244 Dose 2Vehicle
Role Function-Restrictive15.5 ± 18.0022.7 ± 23.6922.3 ± 24.53
Role Function-Preventive10.7 ± 16.8916.1 ± 22.2112.5 ± 22.04
Emotional Function11.8 ± 24.7719.0 ± 27.1620.2 ± 27.95
Other pre-specifiedMean Change in Days Where Subject Recorded Migraine Associated Symptoms: Nausea/Vomiting, Photophobia and Sonophobia.

Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine associated symptoms: nausea/vomiting, photophobia and sonophobia.

Time frame:
Baseline to Day 112
Reported as:
Mean · days
Mean Change in Days Where Subject Recorded Migraine Associated Symptoms: Nausea/Vomiting, Photophobia and Sonophobia.
daysB244 Dose 1B244 Dose 2Vehicle
Change from Baseline to Week 12-2.3 ± 4.68-2.8 ± 3.49-2.9 ± 3.56
Change from Baseline to Week 16-1.6 ± 4.61-2.0 ± 3.93-1.6 ± 4.21

Adverse events

Collected over Baseline to Day 112. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B244 Dose 10/105 (0%)3/105 (2.9%)45/105 (42.9%)
B244 Dose 20/104 (0%)0/104 (0%)42/104 (40.4%)
Vehicle0/104 (0%)0/104 (0%)49/104 (47.1%)
Most frequent serious events
Most frequent serious events
EventB244 Dose 1B244 Dose 2Vehicle
AsthmaRespiratory, thoracic and mediastinal disorders2/1050/1040/104
CholelithiasisHepatobiliary disorders1/1050/1040/104
Most frequent other events
Showing 10 of 131
Most frequent other events
EventB244 Dose 1B244 Dose 2Vehicle
Upper respiratory tract infectionInfections and infestations5/10510/1044/104
NasopharyngitisInfections and infestations3/1052/1045/104
EpistaxisRespiratory, thoracic and mediastinal disorders5/1054/1041/104
Nasal congestionRespiratory, thoracic and mediastinal disorders2/1054/1043/104
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/1053/1044/104
CoughRespiratory, thoracic and mediastinal disorders0/1053/1041/104
InfluenzaInfections and infestations3/1051/1041/104
Nasal drynessRespiratory, thoracic and mediastinal disorders3/1051/1042/104
SneezingRespiratory, thoracic and mediastinal disorders3/1050/1041/104
BronchitisInfections and infestations1/1052/1041/104

Baseline characteristics

Intent-to-Treat Population included all randomized subjects who received at least 1 dose of IP and had 80% ePRO diary compliance. Subjects were analyzed according to the treatment assigned by the randomization schedule.

Age, Customized
Age, Customized(Participants)B244 Dose 1B244 Dose 2VehicleTotal
<3016121644
≥30768272230
Sex: Female, Male
Sex: Female, Male(Participants)B244 Dose 1B244 Dose 2VehicleTotal
Female827676234
Male10181240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B244 Dose 1B244 Dose 2VehicleTotal
Hispanic or Latino10101434
Not Hispanic or Latino828472238
Unknown or Not Reported0022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B244 Dose 1B244 Dose 2VehicleTotal
American Indian or Alaska Native0011
Asian3115
Native Hawaiian or Other Pacific Islander0000
Black or African American27212068
White616966196
More than one race0000
Unknown or Not Reported1304
Weight
Weight(kg)B244 Dose 1B244 Dose 2VehicleTotal
Mean85.09 ± 25.83593.33 ± 22.79189.34 ± 25.94085.85 ± 24.903
Height
Height(m)B244 Dose 1B244 Dose 2VehicleTotal
Mean1.66 ± 0.0841.66 ± 0.1111.66 ± 0.0891.66 ± 0.095
BMI
BMI(kg/m^2)B244 Dose 1B244 Dose 2VehicleTotal
Mean30.51 ± 8.56930.55 ± 9.18331.99 ± 8.22931.00 ± 8.675
BMI Category
BMI Category(Participants)B244 Dose 1B244 Dose 2VehicleTotal
<20 kg/m^22327
20-<25 kg/m^223261766
25-<30 kg/m^230201969
≥30 kg/m^2374550132

12 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • CI Trials
    Riverside, California 92506, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • New England Institute for Neurology and Headache (NEINH)/Medical Practice
    Stamford, Connecticut 06905, United States
  • Clinical Neuroscience Solution, Inc
    Jacksonville, Florida 32256, United States
  • Precision Clinical Research
    Lauderdale Lakes, Florida 33319, United States
  • Clinical Neuroscience Solution, Inc
    Orlando, Florida 32801, United States
  • Palm Beach Research
    West Palm Beach, Florida 33409, United States
  • Neurostudies Clinical Research
    Decatur, Georgia 30033, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • MedVadis Research
    Watertown, Massachusetts 02472, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Rochester Clinical Research INC
    Rochester, New York 14609, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29406, United States
  • Clinical Neuroscience Solution, Inc
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology and Sleep Lab, L.P.
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, L.P.
    Dallas, Texas 75231, United States
  • Texas Center for Drug Development
    Houston, Texas 77081, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jun 2019, 14 months.

Results were first posted in Oct 2022, 3 years 3 months after primary completion. A results delay was requested in Jul 2020.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 14 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 5, 2018
StartActual
Mar 30, 2018
Primary completionActual
Jun 17, 2019
CompletionActual
Jul 16, 2019
Results delay requested
Jul 28, 2020
Results first posted
Oct 4, 2022
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03488563
Lead sponsor
AOBiome LLC
Collaborators
Veristat, Inc.
Responsible party
Sponsor
First posted
Apr 5, 2018
Start date
Mar 30, 2018
Primary completion
Jun 17, 2019
Completion
Jul 16, 2019
Results posted
Oct 4, 2022
Last update
Oct 4, 2022

Study contacts

Judith Ng-Cashin, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion